Cargando…

The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer

The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data of 124 consecutive patients, who underwent primary resection for vulvar ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Onoprienko, Arina, Hofstetter, Gerda, Dorittke, Tim, Bekos, Christine, Grimm, Christoph, Polterauer, Mariella, Bartl, Thomas, Polterauer, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694316/
https://www.ncbi.nlm.nih.gov/pubmed/36579608
http://dx.doi.org/10.3390/jpm12111882
_version_ 1784837769882763264
author Onoprienko, Arina
Hofstetter, Gerda
Dorittke, Tim
Bekos, Christine
Grimm, Christoph
Polterauer, Mariella
Bartl, Thomas
Polterauer, Stephan
author_facet Onoprienko, Arina
Hofstetter, Gerda
Dorittke, Tim
Bekos, Christine
Grimm, Christoph
Polterauer, Mariella
Bartl, Thomas
Polterauer, Stephan
author_sort Onoprienko, Arina
collection PubMed
description The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data of 124 consecutive patients, who underwent primary resection for vulvar cancer ≥ pT1b, were retrospectively analyzed. Associations between the FARI and disease recurrence were assessed fitting receiver operating characteristics (ROC) and binary logistic regression models; univariate and multivariable Cox regression models for disease-specific survival (DSS) and progression-free survival (PFS) were performed. A pretherapeutic low FARI cut at its median (<9.67) is significantly associated with younger age (65.5 vs. 74.0 years) and higher risk of recurrence (52.4% vs. 26.2%). The ROC analysis calculates the area under the curve (AUC) of the FARI for a PFS < 6 months of 0.700 and for a DSS < 12 months of 0.706, outperforming fibrinogen and albumin alone. The FARI remained independently predictive for PFS (HR 0.84, 95% CI [0.99–1.03], p = 0.009) and DSS (HR 0.82, 95% CI [0.70–0.99], p = 0.019), also in multivariable survival analysis. Despite the FARI’s promising predictive and prognostic value, however, further elucidation of its precise mode of action is warranted before clinical application as it appears to rely only on subtle changes of fibrinogen levels.
format Online
Article
Text
id pubmed-9694316
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96943162022-11-26 The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer Onoprienko, Arina Hofstetter, Gerda Dorittke, Tim Bekos, Christine Grimm, Christoph Polterauer, Mariella Bartl, Thomas Polterauer, Stephan J Pers Med Article The present study aims to evaluate the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI), as currently reliable biomarkers to predict therapy response and prognosis of patients with advanced vulvar cancer are missing. Data of 124 consecutive patients, who underwent primary resection for vulvar cancer ≥ pT1b, were retrospectively analyzed. Associations between the FARI and disease recurrence were assessed fitting receiver operating characteristics (ROC) and binary logistic regression models; univariate and multivariable Cox regression models for disease-specific survival (DSS) and progression-free survival (PFS) were performed. A pretherapeutic low FARI cut at its median (<9.67) is significantly associated with younger age (65.5 vs. 74.0 years) and higher risk of recurrence (52.4% vs. 26.2%). The ROC analysis calculates the area under the curve (AUC) of the FARI for a PFS < 6 months of 0.700 and for a DSS < 12 months of 0.706, outperforming fibrinogen and albumin alone. The FARI remained independently predictive for PFS (HR 0.84, 95% CI [0.99–1.03], p = 0.009) and DSS (HR 0.82, 95% CI [0.70–0.99], p = 0.019), also in multivariable survival analysis. Despite the FARI’s promising predictive and prognostic value, however, further elucidation of its precise mode of action is warranted before clinical application as it appears to rely only on subtle changes of fibrinogen levels. MDPI 2022-11-10 /pmc/articles/PMC9694316/ /pubmed/36579608 http://dx.doi.org/10.3390/jpm12111882 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Onoprienko, Arina
Hofstetter, Gerda
Dorittke, Tim
Bekos, Christine
Grimm, Christoph
Polterauer, Mariella
Bartl, Thomas
Polterauer, Stephan
The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
title The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
title_full The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
title_fullStr The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
title_full_unstemmed The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
title_short The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
title_sort prognostic value of the fibrinogen-albumin-ratio index (fari) in patients with advanced vulvar cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694316/
https://www.ncbi.nlm.nih.gov/pubmed/36579608
http://dx.doi.org/10.3390/jpm12111882
work_keys_str_mv AT onoprienkoarina theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT hofstettergerda theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT dorittketim theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT bekoschristine theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT grimmchristoph theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT polterauermariella theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT bartlthomas theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT polterauerstephan theprognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT onoprienkoarina prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT hofstettergerda prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT dorittketim prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT bekoschristine prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT grimmchristoph prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT polterauermariella prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT bartlthomas prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer
AT polterauerstephan prognosticvalueofthefibrinogenalbuminratioindexfariinpatientswithadvancedvulvarcancer